BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Atogepant (Qulipta) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Atogepant (Qulipta)\, from ClinicalTrials
 .gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05711394-10367@assetmemo.bio
DTSTAMP:20261121T004950Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Atogepant (Qulipta): Phase 3 readout est. (NCT05711394)
DESCRIPTION:Atogepant (Qulipta)\, phase 3\, Migraine.\nStudy: A Study to As
 sess the Adverse Events and Change in Disease Activity of Oral Atogepant T
 ablets in Pediatric Participants (6-17 Years of Age) With Episodic Migrain
 e\nEstimated primary completion: March 2028. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/atogepant-qulipta#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT05711394
URL:https://assetmemo.bio/drug/atogepant-qulipta#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07826910-10367@assetmemo.bio
DTSTAMP:20261121T004950Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Atogepant (Qulipta): Phase 4 readout est. (NCT07826910)
DESCRIPTION:Atogepant (Qulipta)\, phase 4\, Migraine.\nStudy: Effect of Ato
 gepant on the Vestibulo-Ocular Reflex in Healthy Adults and Adults With Mi
 graine\nEstimated primary completion: December 2028. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/atogepant-qulipta#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT07826910
URL:https://assetmemo.bio/drug/atogepant-qulipta#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06972056-10367@assetmemo.bio
DTSTAMP:20261121T004950Z
DTSTART;VALUE=DATE:20290301
DTEND;VALUE=DATE:20290302
SUMMARY:Atogepant (Qulipta): Phase 4 readout est. (NCT06972056)
DESCRIPTION:Atogepant (Qulipta)\, phase 4\, Migraine.\nStudy: Comparative E
 ffectiveness of Migraine Preventive Medications: The APT Comparison Study\
 nEstimated primary completion: 1 March 2029. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/atogepant-qulipta#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT06972056
URL:https://assetmemo.bio/drug/atogepant-qulipta#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06810505-10367@assetmemo.bio
DTSTAMP:20261121T004950Z
DTSTART;VALUE=DATE:20310331
DTEND;VALUE=DATE:20310401
SUMMARY:Atogepant (Qulipta): Phase 3 readout est. (NCT06810505)
DESCRIPTION:Atogepant (Qulipta)\, phase 3\, Migraine.\nStudy: A Study of Or
 al Atogepant Tablets to Assess Adverse Events and Change in Disease Activi
 ty To Prevent Migraine in Participants Aged 12 to 17 Years\nEstimated prim
 ary completion: March 2031. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/atogepant-qulipta#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT06810505
URL:https://assetmemo.bio/drug/atogepant-qulipta#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07655440-10367@assetmemo.bio
DTSTAMP:20261121T004950Z
DTSTART;VALUE=DATE:20310731
DTEND;VALUE=DATE:20310801
SUMMARY:Atogepant (Qulipta): Phase 4 readout est. (NCT07655440)
DESCRIPTION:Atogepant (Qulipta)\, phase 4\, Migraine.\nStudy: Comparing Mig
 raine Preventive Therapies vs. Anti-CGRP Therapies for Tinnitus in Patient
 s With Migraine (COMPACT-PM)\nEstimated primary completion: July 2031. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/atogepant-qulipta#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT07655440
URL:https://assetmemo.bio/drug/atogepant-qulipta#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05707949-10367@assetmemo.bio
DTSTAMP:20261121T004950Z
DTSTART;VALUE=DATE:20320430
DTEND;VALUE=DATE:20320501
SUMMARY:Atogepant (Qulipta): Phase 3 readout est. (NCT05707949)
DESCRIPTION:Atogepant (Qulipta)\, phase 3\, Migraine.\nStudy: Long-term Ext
 ension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatr
 ic Participants (6 to 17 Years of Age) With Migraine\nEstimated primary co
 mpletion: April 2032. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /atogepant-qulipta#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT05707949
URL:https://assetmemo.bio/drug/atogepant-qulipta#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
